# A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

> **NCT01225731** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 355 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** tildrakizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01225731
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-25
- **Primary completion:** 2011-11-04
- **Final completion:** 2012-10-24
- **Target enrollment:** 355 (ACTUAL)
- **Last updated:** 2019-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01225731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01225731, "A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01225731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*